Recurred after taking Olaparib for 4 months

Olaparib is the first oral PARPi of its kind, and previous studies have shown that patients with ovarian cancer with germline BRCA mutations that are resistant to multiple lines of chemotherapy can benefit from olaparib monotherapy, with a median progression-free survival (PFS) of 7 months and an overall survival (OS) of 16.6 months.

StudiesBoth studies 19 and SOLO2 showed that in patients with platinum-sensitive recurrent serous ovarian cancer without BRCA mutations or BRCA mutations, maintenance treatment with olaparib significantly increased PFS without any adverse impact on quality of life. Additionally, the favorable results for SOLO1 demonstrate that olaparib provides significant clinical benefit in women newly diagnosed with BRCA1/2-mutated advanced ovarian cancer. Across the four arms of the study, all patients experienced adverse reactions (AEs). The most common adverse reactions were fatigue, loss of appetite, anemia, nausea and vomiting. Most patients experienced grade 1-2 AEs. Adverse reactions were usually managed by interrupting or reducing the dose rather than discontinuing the drug.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.